# Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

> **NCT03153319** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center** · enrollment: 14 (estimated)

## Conditions studied

- Mucopolysaccharidosis I
- Mucopolysaccharidosis II
- Mucopolysaccharidosis VI

## Interventions

- **DRUG:** Adalimumab Injection [Humira]
- **DRUG:** Saline Solution for Injection

## Key facts

- **NCT ID:** NCT03153319
- **Lead sponsor:** Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-06-05
- **Primary completion:** 2027-01
- **Final completion:** 2027-02
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2026-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03153319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03153319, "Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03153319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*